Sample Collection, Biobanking, and Standard AD Biomarker Testing

What this project does
Builds and maintains a high-quality biobank (blood + optional CSF), and measures the standard Alzheimer’s biomarkers so results are comparable across ADRCs.

Why it matters clinically
These are the biomarkers clinicians hear about most (amyloid, tau, neurodegeneration markers). Standardized measurement helps confirm disease biology, stage disease, and supports future treatment stratification.

Key activities
-Coordinate biospecimen handling linked to clinical data (with strict timing/quality standards)
-Collect annual blood samples from all participants; collect CSF from a subset
-Ship required samples to national repositories (e.g., NCRAD) and bank selected materials locally
-Measure established AD biomarkers (e.g., Aβ40/42, p-tau217, GFAP, NfL) using validated platforms

What will be delivered
-A banked, well-annotated biospecimen library linked to clinical data
-Standard biomarker datasets shared with the ADRC community and national databases

Who this helps
-Clinicians and investigators enrolling participants
-Researchers doing cross-center comparisons
-Future trials needing standardized biological measures